Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.
Coriat
Romain
R
Center for Research on Angiogenesis Inhibitor, Université Paris Descartes, AP-HP, Teaching Hospital Cochin, Paris, France. romain.coriat@cch.aphp.fr
Ropert
Stanislas
S
Mir
Olivier
O
Billemont
Bertrand
B
Chaussade
Stanislas
S
Massault
Pierre-Philippe
PP
Blanchet
Benoit
B
Vignaux
Olivier
O
Goldwasser
François
F
D000328:Adult; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011006:Pneumatosis Cystoides Intestinalis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D011859:Radiography; D000077157:Sorafenib; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib